There is a growing need for new antibacterial agents owing to appearance of multi-resistant organisms in hospitals. Although resistance is less of a problem in the community, there is a danger of the spread of resistance genes from hospital strains to epidemic strains in the community. This might be happening with methicillin resistance in *Staphylococcus aureus*, which became a significant problem in hospitals around the world during the 1980s and began to appear in community strains that were otherwise quite susceptible in the early 1990s. The community-acquired strains carry genes for toxin production and therefore are associated with higher morbidity and mortality than the hospital strains. The accumulation of resistance in the community is slower: new outbreaks tend to be sporadic and the resistant organisms might simply be diluted out from the greater pool of susceptible organisms in the absence of the intense selection pressure imposed by high antibiotic usage. Nevertheless, clones of penicillin-resistant *Streptococcus pneumoniae* have spread around the world and the transmission of such organisms could become more rapid as people become more mobile.

New viruses number highly among the emergent diseases and there is continued speculation about the consequences of one of these becoming truly epidemic with no available vaccination. Furthermore, development of resistance towards chemotherapeutic agents currently employed for treatment of human immunodeficiency virus (HIV) infection is proving to be rapid and is driving the quest for the development of new agents and for new combinations of existing agents. Resistance development and emergent diseases have thrown current drug discovery efforts into the forefront of debate. One question that is frequently asked is "where are the new drugs going to come from?" --- a theme that is taken up in this section.

[John Barrett](10.1016/j.mib.2005.08.007) addresses the possibility that smaller biotech companies could take over the traditional role of large pharmaceutical companies in bringing new antibacterial agents into the clinic. As he clearly identifies, the major hurdle for small companies is the cost of late stage clinical trials. Cubist were able to licence daptomycin from Eli Lilly and to bring it onto the market in 2003 as Cubicin^®^ for treatment of complicated skin and soft tissue infections caused by Gram-positive bacteria. This was at the cost of a large part of the internal research organisation on which the company was originally founded. Similarly, Oscient Pharmaceuticals brought gemifloxacin, in-licensed from GlaxoSmithKline, to the market in 2004 for treatment of community-acquired pneumonia and acute exacerbation of chronic bronchitis. Like Cubist, Oscient started life on research platforms: Genome Therapeutics (high-throughput DNA sequencing) merged with GeneSoft Pharmaceuticals (discovery of DNA-binding small molecules) and used the acquired critical mass to concentrate on development of in-licensed clinical candidates (gemifloxacin and ramoplanin in the antibacterial field).

An alternative strategy that might allow continued support for internal research base is exemplified by another example discussed by [John Barrett](10.1016/j.mib.2005.08.007): Paratek Pharmaceutical built a discovery platform around novel tetracycline chemistry and, rather than bear the development cost, partnered with Bayer early in the clinical programme. A similar strategy has been followed in Europe by Basilea Pharmaceutica, which announced earlier this year that they have partnered with Johnson & Johnson to continue the development of ceftobiprole in phase III clinical trials. An additional recent example is the announcement that Pfizer would acquire the small biotech company Vicuron for development of an antifungal and an antibacterial drug that had each completed phase III trials.

The answer to [John Barrett\'s](10.1016/j.mib.2005.08.007) question, "Can biotech deliver new antibiotics?" appears to be a qualified yes. Yes, products can move forward, but possibly at the expense of maintaining a full pipeline that will ensure continued survival of the company.

An issue highlighted by [John Barrett](10.1016/j.mib.2005.08.007) is that the investigational and recently introduced antibacterial agents encompass relatively narrow microbial spectra and could be susceptible to particular resistance mechanisms. [Holland and Kiechle](10.1016/j.mib.2005.08.001) discuss recent advances in the use of point-of-care (POC) diagnostic systems. These could give rapid identification of infectious agents and antimicrobial resistance, which would facilitate the decision-making of the infectious disease expert when faced with a critically ill patient. [Holland and Kiechle](10.1016/j.mib.2005.08.001) profile nine companies that are working to bring antimicrobial testing to the patient\'s bedside. These new testing methods will provide the answer in 'real time', which will enable accurate diagnosis and treatment of infection and thus should decrease morbidity and mortality. Rapid accurate diagnosis will also make it easier to use narrow-spectrum drugs that are best suited to treatment of the infection in the patient at hand, which will help to control the development of resistance through commensal exposure. A further benefit, particularly in developing countries, is that the technologies under development could be accessible to institutions that cannot afford to maintain a central laboratory for testing in the traditional way.

Infections in hospitals caused by multi-resistant Gram-positive agents have received much attention both in the scientific and the popular press, sometimes eliciting sensational headlines: "Medical team tracks killer bugs" (Birmingham Business Journal, 15 August 2003) or "News probe sparks action call to wipe out killer superbugs" (Scottish Evening News, 4 June 2005). Of the 20 investigational drugs discussed by [Barrett](10.1016/j.mib.2005.08.007), 15 are either only active against Gram-positive bacteria or have activity against Gram-positive bacteria as one of the major differentiating features. [Appelbaum and Jacobs](10.1016/j.mib.2005.07.001) give a succinct, detailed overview of the latest developments in this field of antimicrobial chemotherapy. As [Appelbaum and Jacobs](10.1016/j.mib.2005.07.001) report, resistance towards antimicrobial agents has reached high levels in the streptococci (∼25% of *S. pneumoniae* are resistant to penicillin in the USA), the staphylococci (∼35% of *S. aureus* are resistant to all available β-lactam antibiotics in the USA) and the enterococci (∼12% of *Enterococci faecalis* are resistant to vancomycin in the USA). Many of the new agents under investigation are members of well-established classes that have been modified to overcome particular resistance mechanisms. For example, ceftobiprole (a cephalosporin) overcomes penicillin-binding protein-mediated resistance in the streptococci and staphylococci; WCK-771 (a quinolone) overcomes established mutational resistance in the streptococci and staphylococci; the recently approved tetracycline, tigecycline (Tygacil^®^ from Wyeth), overcomes both efflux-mediated and ribosome protection resistance in the streptococci and staphylococci; and oritavancin (a glycopeptide) overcomes vancomycin resistance in the enterococci. There are far fewer agents of new classes that completely circumvent established resistance. [Appelbaum and Jacobs](10.1016/j.mib.2005.07.001) report on the activities of the inhibitors of peptidyl deformylase. These show moderate activity against streptococci and staphylococci, regardless of their established resistance profile. Many of the agents are only available as injectable formulations, and whereas some, such as ceftobiprole, belong to classes that have a well-recognized safety profile, others belong to classes that carry a greater history of adverse events. There are not many orally available antibacterials that can be used for the treatment of infections caused by multi-resistant Gram-positive bacteria.

In contrast to the high proportion of agents that have activity against Gram-positive bacteria, there are few agents currently in development for treatment of severe infections caused by Gram-negative bacteria. [Thomson and Bonomo](10.1016/j.mib.2005.08.014) discuss the challenges that face the continued use of β-lactam antibiotics, which have been one of the major therapeutic choices for these organisms to date. Problem pathogens identified by [Thomson and Bonomo](10.1016/j.mib.2005.08.014) include *Pseudomonas aeruginosa*, which they consider to be the most formidable pathogen found in the hospital setting. It is of importance in infections of cystic fibrosis, in neutropenic patients and in hospital-acquired pneumonias (especially ventilator-associated pneumonia). An overlapping set of broad-spectrum efflux pumps give this organism ready access to a multi-drug phenotype that can make strains untreatable by all available antibiotics. Another organism of concern is *Acinetobacter baumannii*, which can also develop multi-resistant strains. Twelve percent of the isolates from a recent outbreak in New York City (USA) were resistant to all available antibiotics. Multi-drug resistance is also of concern in *Klebsiella pneumoniae*, an organism that seems particularly able to share resistance determinants once acquired on mobile elements. Amongst the β-lactams, the cephalosporins, carbapenems and penicillin/β-lactamase inhibitor combinations have proven successful for the treatment of Gram-negative pathogens.

[Thomson and Bonomo](10.1016/j.mib.2005.08.014) also report on the increasing number of β-lactamases that are able to hydrolyse carbapenems and cephalosporins. Increased usage of carbapenems, as generics become readily available and as the usage of cephalosporins is restricted owing to extended-spectrum β-lactamases, will only encourage the appearance and spread of more carbapenemases. Among the newly approved and investigational agents, we find little to address the problem of resistance in Gram-negative bacteria. Ceftobiprole, doripenem, faropenem and tebipenem have significant Gram-negative activity, but are susceptible to many of the carbapenemases. Tigecycline is active against some Enterobacteriaceae and *Acinetobacter*, but is inactive against *Pseudomonas aeruginosa* and resistant strains of *Klebsiella pneumoniae* are already known. This is an area in which new agents need to be developed before significant numbers of patients suffer from infections with multi-resistant organisms.

Understanding the molecular basis of the mechanisms of resistance can help in the design of new molecules that incorporate features to overcome or to circumvent this resistance. [Wilke *et al*](10.1016/j.mib.2005.08.016). review current knowledge of the resistance mechanisms towards the β-lactam antibiotics discussed by [Thomson and Bonomo](10.1016/j.mib.2005.08.014). Three-dimensional structures of the penicillin-binding proteins (PBPs) that are the target of β-lactam antibiotics (and, in the case of the staphylococcal PBP2a, can also be the major resistant determinant) clearly help in the design of new inhibitors that are active against both sensitive and resistant PBPs. Understanding the structure and the mechanism of β-lactamases has helped to design new classes of β-lactamase inhibitors that can be combined with β-lactam antibiotics.

A greater challenge is to utilise the structures of efflux pumps that are now becoming available to design compounds that are no longer substrates for these broad-spectrum resistance determinants. Another aim is to design compounds that act as inhibitors to these pumps; these can then be combined with antibiotic substrates to protect them against forced efflux. [Joyce Sutcliffe](10.1016/j.mib.2005.08.004) continues this theme by describing the progress made in determination of the structure of the bacterial ribosome subunits and of the binding mode of some of the multitude of antibiotics known to inhibit the ribosome. This data has provided the starting points for a number of knowledge-based design programmes that aim to modify existing classes of antibiotics to elicit new binding modes that will escape known modifications of the ribosome structure.

Natural products have long been a fruitful source of antibiotics and many of the new agents discussed in the articles of this section stem from a natural product precursor. [Patton and van der Donk](10.1016/j.mib.2005.08.008) describe the lantibiotics, an unusual group of post-translationally modified peptidic antibiotics produced by Gram-positive bacteria. Nisin, one of the best known of these, is used as a food preservative in more than 50 countries and has attracted attention for its potential use in control of *Helicobacter pylori*. The related epidermins have been investigated for use in acne as they are active against *Propionibacterium acnes*, and mersacidin has recently attracted attention because of its *in vivo* activity against methicilli-resistant staphylococci and vancomycin-resistant enterococci.

Although many of the factors that confront the discovery and development of new antibacterial agents (e.g. acute therapy, resistance development, emerging diseases and increasing vulnerable population) are superficially similar for new antiviral agents, industrial commitment to discovery of new antivirals has remained stronger than it has for antibacterials or antifungals. This could be because few antivirals actually work as acute therapy and once a patient with, for example, HIV has started a course of therapy they will continue to take it for some time. Resistance development and the emergence of new viral strains such as severe acute respiratory syndrome coronavirus and H~5~N~1~ influenza virus, for which there are no vaccines available, have put much emphasis on chemotherapeutic approaches, which are summarized by [De Clercq](10.1016/j.mib.2005.08.010).

The collection of articles in this section illuminates several of the contemporary issues that face the challenges of discovery and development of new anti-infective agents. These include basic studies of the mechanism of action of new and established molecular classes and the modes of resistance development. The dramatic increase in knowledge about the architecture of bacterial ribosomes is one leverage point for the rational design of new antibiotics. This section also surveys agents in development for treatment of Gram-positive and Gram-negative bacterial infections and of viral infections. It provides a direct assessment of the opportunity for small biotechnology companies to provide innovation in discovery and development in this area of research.
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